financetom
Business
financetom
/
Business
/
Steris Fiscal Q4 Non-GAAP EPS, Revenue Rise; Fiscal 2025 Outlook Set -- Share Rise After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Steris Fiscal Q4 Non-GAAP EPS, Revenue Rise; Fiscal 2025 Outlook Set -- Share Rise After Hours
May 8, 2024 2:44 PM

05:21 PM EDT, 05/08/2024 (MT Newswires) -- Steris ( STE ) reported fiscal Q4 adjusted net income late Wednesday of $2.58 per diluted share, up from $2.30 a year earlier.

Analysts polled by Capital IQ expected $2.35.

Revenue for the quarter ended March 31 was $1.52 billion, up from $1.38 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.41 billion.

For fiscal 2025, the company is projecting non-GAAP EPS of $9.05 to $9.25 with revenue from continuing operations expected to increase 6.5% to 7.5%.

Analysts polled by Capital IQ are looking for EPS of $9.33 on revenue of $5.67 billion, respectively.

Share of the company rose 4% in after-hours trading.

Price: 218.50, Change: +8.41, Percent Change: +4.00

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025
Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025
Oct 22, 2024
Quest Diagnostics Inc posted third-quarter adjusted earnings per share of $2.30, beating the consensus of $2.26. Sales increased 8.5% year-over-year to $2.49 billion, beating the consensus of $2.42 billion. Quest Diagnostics ( DGX ) saw total revenue growth of 8.5%, including 4.2% organic growth, said Quest Diagnostics CEO Jim Davis. “Our performance was driven by new customer wins and expanded business with physicians...
Sangamo Therapeutics Shares Surge After US FDA Clears Potential Fabry Disease Treatment for Expedited Review
Sangamo Therapeutics Shares Surge After US FDA Clears Potential Fabry Disease Treatment for Expedited Review
Oct 22, 2024
11:10 AM EDT, 10/22/2024 (MT Newswires) -- Sangamo Therapeutics ( SGMO ) shares surged past 31% in recent Tuesday trading after the genomic medicine company said the US Food and Drug Administration has laid out a clear pathway for accelerated approval for its ST-920 gene therapy candidate for the treatment of Fabry disease. Fabry disease is a genetic condition characterized...
Hesai Technology to Exclusively Provide Lidar for New Leapmotor Models
Hesai Technology to Exclusively Provide Lidar for New Leapmotor Models
Oct 22, 2024
11:13 AM EDT, 10/22/2024 (MT Newswires) -- Hesai Technology said Tuesday it will exclusively supply long-range lidar for Leapmotor's new models, with the first model slated for mass production in 2025. Under the agreement, Hesai ( HSAI ) said it will provide lidar systems for multiple upcoming models, expanding the companies' collaboration on intelligent driving systems. Hesai ( HSAI )...
US working 'as fast as we can' to finalize EV conversion grants, official says
US working 'as fast as we can' to finalize EV conversion grants, official says
Oct 22, 2024
* DOE announced $1.7 billion in grants for EV plant conversions * UAW threatens strikes over Stellantis ( STLA ) delays in Belvidere investment * Granholm emphasizes Biden administration's commitment to EV production By David Shepardson, Nora Eckert DETROIT, Oct 22 (Reuters) - U.S. Energy Secretary Jennifer Granholm said Tuesday the department is working as fast as we can to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved